ACADIA Pharmaceuticals (NASDAQ:ACAD – Free Report) had its price objective reduced by JPMorgan Chase & Co. from $34.00 to $33.00 in a report issued on Monday morning,Benzinga reports. Deutsche Bank Aktiengesellschaft set a $29.00 price target on ACADIA Pharmaceuticals in a research note on Thursday. Get ACADIA Pharmaceuticals alerts:View Our Latest Research Report on ACADIA PharmaceuticalsACADIA Pharmaceuticals Stock PerformanceACAD stock opened at $21.32 on Monday. ACADIA Pharmaceuticals (NASDAQ:ACAD – Get Free Report) last released its quarterly earnings results on Wednesday, August 6th. Read MoreReceive News & Ratings for ACADIA Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ACADIA Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.